ENXTBR:MITRA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. More Details


Snowflake Analysis

High growth potential with imperfect balance sheet.


Similar Companies

Share Price & News

How has Mithra Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MITRA has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-0.2%

MITRA

-1.6%

BE Pharmaceuticals

-1.1%

BE Market


1 Year Return

-36.2%

MITRA

-1.1%

BE Pharmaceuticals

-19.7%

BE Market

Return vs Industry: MITRA underperformed the Belgian Pharmaceuticals industry which returned -0.8% over the past year.

Return vs Market: MITRA underperformed the Belgian Market which returned -19% over the past year.


Shareholder returns

MITRAIndustryMarket
7 Day-0.2%-1.6%-1.1%
30 Day0.7%-6.0%1.4%
90 Day-3.5%-17.3%-2.7%
1 Year-36.2%-36.2%2.0%-1.1%-18.4%-19.7%
3 Year50.3%50.3%22.9%8.8%-27.1%-31.5%
5 Year93.7%93.7%22.9%1.8%-21.2%-29.3%

Price Volatility Vs. Market

How volatile is Mithra Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Mithra Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.99x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: MITRA (€16.9) is trading above our estimate of fair value (€14.86)

Significantly Below Fair Value: MITRA is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: MITRA is unprofitable, so we can't compare its PE Ratio to the XE Pharmaceuticals industry average.

PE vs Market: MITRA is unprofitable, so we can't compare its PE Ratio to the Belgian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MITRA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MITRA's PB Ratio (4x) is in line with the BE Pharmaceuticals industry average.


Next Steps

Future Growth

How is Mithra Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

66.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: MITRA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: MITRA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: MITRA's is expected to become profitable in the next 3 years.

Revenue vs Market: MITRA's revenue (29.7% per year) is forecast to grow faster than the Belgian market (6.8% per year).

High Growth Revenue: MITRA's revenue (29.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if MITRA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Mithra Pharmaceuticals performed over the past 5 years?

-33.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MITRA is currently unprofitable.

Growing Profit Margin: MITRA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MITRA is unprofitable, and losses have increased over the past 5 years at a rate of 33.1% per year.

Accelerating Growth: Unable to compare MITRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MITRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13.1%).


Return on Equity

High ROE: MITRA has a negative Return on Equity (-16.67%), as it is currently unprofitable.


Next Steps

Financial Health

How is Mithra Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: MITRA's short term assets (€91.5M) exceed its short term liabilities (€47.8M).

Long Term Liabilities: MITRA's short term assets (€91.5M) do not cover its long term liabilities (€186.5M).


Debt to Equity History and Analysis

Debt Level: MITRA's debt to equity ratio (89.4%) is considered high.

Reducing Debt: MITRA's debt to equity ratio has reduced from 90.8% to 89.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MITRA has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MITRA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Mithra Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MITRA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MITRA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MITRA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MITRA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: MITRA is not paying a notable dividend for the Belgian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MITRA's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Francois Fornieri

no data

Tenure

Mr. Francois Fornieri served as a Director of VOO until March 29, 2017. Mr. Fornieri serves as the Chief Executive Officer and Chief Business Development Officer at Mithra Pharmaceuticals SA. Mr. Fornieri ...


Leadership Team

NamePositionTenureCompensationOwnership
Francois Fornieri
CEO, Chief Business Development Officer & Executive Directorno datano data25.54%
€ 184.4m
Christophe Maréchal
Chief Financial Officer3.67yrsno datano data
Graham Dixon
Chief Scientific Officer1.25yrsno datano data
Alexandra Deschner
Investor Relations Officer1.67yrsno datano data
Jean-Michel Foidart
President of the Scientific Advisory Board & Executive Directorno data€7.12k0.097%
€ 700.6k
Benjamin Brands
Chief Supply Chain Officer2.75yrsno datano data
Renaat Baas
Chief Production Officerno datano datano data

2.2yrs

Average Tenure

Experienced Management: MITRA's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Francois Fornieri
CEO, Chief Business Development Officer & Executive Directorno datano data25.54%
€ 184.4m
Jean-Michel Foidart
President of the Scientific Advisory Board & Executive Directorno data€7.12k0.097%
€ 700.6k
Marc Armand Alice André Coucke
Non-Executive Chairman4.08yrs€40.00kno data
Philippe Suinen
Independent Directorno data€25.00kno data
Koen Hoffman
Independent Director4.08yrs€25.00kno data
Gaëtan Servais
Non-Executive Directorno data€30.00kno data
Guy Debruyne
Non Executive Directorno data€20.00k0.19%
€ 1.4m
Jacques Platieau
Independent Directorno data€25.00k0.0037%
€ 27.1k
Freya Loncin
Non-Executive Director4.08yrs€20.00kno data
Christiane Malcorps
Independent Directorno data€25.00kno data
Patricia Dijck
Independent Director1.75yrs€10.00kno data
Joanna Tyrekidis
Non-Executive Director1.75yrs€10.00kno data

4.1yrs

Average Tenure

52yo

Average Age

Experienced Board: MITRA's board of directors are considered experienced (4.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.3%.


Top Shareholders

Company Information

Mithra Pharmaceuticals SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Mithra Pharmaceuticals SA
  • Ticker: MITRA
  • Exchange: ENXTBR
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €721.868m
  • Shares outstanding: 42.71m
  • Website: https://www.mithra.com

Number of Employees


Location

  • Mithra Pharmaceuticals SA
  • Rue Saint-Georges 5
  • Liège
  • Liège
  • 4000
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MITRAENXTBR (Euronext Brussels)YesCommon SharesBEEURJun 2015
MITRAbBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJun 2015
0R91LSE (London Stock Exchange)YesCommon SharesGBEURJun 2015
1TMDB (Deutsche Boerse AG)YesCommon SharesDEEURJun 2015
MITP.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJun 2015

Biography

Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Its development can ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/27 21:58
End of Day Share Price2020/10/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.